Author: Editor

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at Cedars-Sinai. In this video, he speaks about the ASCO 2022 Abstract – Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). Origins: HRLPC is currently managed with long-term ADT and main RT. Despite receiving definitive primary care, these patients face a high risk of metastases and mortality. The phase 3 ATLAS research (NCT02531516)…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Michael B. Atkins, MD, Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center, William M. Scholl Professor and Vice-Chair Department of Oncology and Professor of Medicine Georgetown University Medical Center. In this video, he speaks about the ASCO 2022 Abstract – Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant metastatic melanoma (MM) (ECOG-ACRIN EA6134). Origins: In patients with BRAFV600 mutant MM, combinations of immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) or BRAF/MEK-targeted treatments showed considerable clinical benefit. Until recently, there was little prospective evidence to advise the…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Diwakar Davar, MBBS, M.Sc, Assistant Professor, Phase I Therapeutics and Melanoma at UPMC. In this video, he speaks about the ASCO 2022 Abstract – Dose Escalation of Davoceticept, a conditional CD28 Costimulator and Dual Checkpoint Inhibitor, in Advanced Malignancies (NEON-1). Origins: Combining checkpoint inhibition (CPI) with T cell costimulatory agonists, notably CD28, a major T cell costimulatory ligand recognized as a significant target of checkpoint inhibition, has a strong preclinical rationale. Davoceticept (ALPN-202) is a PD-L1-dependent CD80 vIgD-Fc fusion that mediates CD28 costimulation and suppresses the PD-L1 and CTLA-4 checkpoints. It has outperformed CPI-only therapy in vitro and in vivo…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study (307). Origins: In the open-label, randomized, phase 3 CLEAR trial, LEN + PEMBRO outperformed SUN in terms of PFS (primary endpoint) and OS (key secondary endpoint) in patients with aRCC in the 1L scenario (Motzer 2021, NEJM). In the CLEAR LEN + PEMBRO and SUN treatment groups, we assessed PFS…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Professor Mary O’Brien, Consultant Medical Oncologist MD FRCP at The Royal Marsden NHS Foundation Trust (RHM), Professor of practice (medical oncology) from Imperial College London. In this video, she speaks about the ASCO 2022 – Discussion – EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use. Origins: Pembrolizumab significantly improved DFS compared to placebo in patients (pts) with completely resected stage IB (T 4 cm) to IIIA NSCLC per AJCC v7, regardless of PD-L1 expression (N = 1177, HR…

Steven Ansell, MD, PhD, Professor of Medicine at Mayo Clinic. In this video, he speaks about the ASCO Abstract – First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Origins: To date, an overall survival (OS) benefit from innovative therapy combinations over conventional treatments in first-line classical Hodgkin lymphoma has seldom been demonstrated (cHL). The development of more active medicines for relapsed/refractory illness has made demonstrating increased OS with first-line therapy difficult. In ECHELON-1 (NCT01712490), 5-year follow-up studies supported the long-term progression-free survival (PFS) benefit of first-line…

The clinical trial that we are discussing is Echelon-1. This is a study specifically for patients with advanced-stage Hodgkin’s lymphoma stages 3 and 4, and it’s a study really evaluating the addition of new novel targets to frontline therapy. Brentuximab vedotin is an antibody-drug conjugate that has been very successful in patients with Hodgkin’s lymphoma in the relapse setting. And now is being tested in the frontline in comparison to ABVD chemotherapy. So, the echelon one trial compared brentuximab vedotin and ABVD chemotherapy. To a standard of care which is ABVD chemotherapy. And the key findings have been reported over…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Ian Krop, MD, Ph.D., Associate Cancer Center Director for Clinical Research; Yale Cancer Center. In this video, he speaks about the ASCO 2022 abstract – 486a – Phase 2 Trial of Tucatinib plus Trastuzumab Deruxetan in Patients with HER2+ Locally Advanced or Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB-04, trial in progress). Origins: Tucatinib is a reversible small-molecule tyrosine kinase inhibitor administered orally that is highly selective for human epidermal growth factor receptor 2. (HER2). Tucatinib is licensed in the United States for treatment in adult patients with HER2+ metastatic breast cancer (MBC), with or without brain metastases,…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Thomas Hope, MD, Associate Professor in Residence at UC San Francisco. In this video, he speaks about the ASCO 2022 Abstract – Imaging of solid tumors using 68Ga-FAP-2286. Origins: Fibroblast Activation Protein (FAP) is a transmembrane protein that is overexpressed on cancer-associated fibroblasts (CAFs) and is prevalent in many epithelial malignancies, implying that FAP is an appealing imaging and therapeutic target. FAP-2286 is a cyclic peptide that binds to FAP and is being tested as a radioligand therapy for patients with FAP-positive solid tumors. It is uncertain what role 68Ga-FAP-2286 plays as a diagnostic agent. We offer an interim investigation…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Pamela Kunz, MD, Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Vice Chief, DEI, Medical Oncology at Yale University. In this video, she speaks about the ASCO 2022 Abstract – A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT as a predictive biomarker (ECOG-ACRIN E2211).   Origins: Advanced pancreatic neuroendocrine tumors (NETs) patients have few therapy choices that result in objective tumor response. According to retrospective and modest prospective studies, the combination of…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Matthew J. Frigault, MD, Clinical Director- Cellular Immunotherapy Program at Mass General Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Phase 1 study of CART-ddBCMA in relapsed or refractory multiple myeloma. Origins: Chimeric Antigen Receptor (CAR) T cell treatments targeting B-cell maturation antigen (BCMA) have shown promise in individuals with relapsed or refractory Multiple Myeloma (RRMM). CART-ddBCMA is an autologous anti-BCMA CAR T cell treatment that employs a unique, synthetic binding domain known as a D-Domain rather than a traditional scFv binder. The goal of this first-in-human experiment is to evaluate CART-safety ddBCMA’s and efficacy.…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Nima Sharifi, MD, director, Center for GU Malignancies Research, Lerner Research Institute, Cleveland Clinic. In this video, he speaks about H3K9 methylation drives resistance to androgen receptor–antagonist therapy in prostate cancer. Relevance This study demonstrates that antiandrogen therapy produces viral mimicking reactions, which are essential for anticancer efficacy. In prostate cancer, H3K9 trimethylation to silence endogenous repeat regions is critical for restoring heterochromatin stability and progressing to antiandrogen resistance. The H3K9 trimethylation mechanism has been linked to poor outcomes in men with prostate cancer, according to our findings. Drug-resistant cancers can be resensitized and cytotoxic interferon responses elicited by blocking…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO Abstract – Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08. History • C-07 was a Phase III clinical trial1 that proved the efficacy of combining oxaliplatin (Oxi) with fluorouracil plus leucovorin (FULV) in adjuvant therapy for patients with stage II and III colon cancer (CC). • Oxi causes neuropathy in 90% of patients; de-escalation will…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for identifying minimal/molecular residual disease (MRD) post-surgery in CC patients (pts), and…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract – A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study. Summary: The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at University of California San Francisco. In this video, she speaks about the Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.  Origins: There are currently no biomarkers that have been validated prospectively in randomized studies for resected colon cancer (CC) to determine the requirement for adjuvant chemotherapy (AC). However, circulating tumor DNA (ctDNA) represents a highly specific and sensitive approach (especially when combined with serial monitoring) for…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Toni Choueiri, MD, Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute. In this video, he speaks about the ASCO 2022 Abstract Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Origins: The first positive phase 3 study of adjuvant immunotherapy for patients (pts) with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions is the double-blind, multicenter, randomized KEYNOTE-564 study (NCT03142334).…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Roger Li, MD, Genitourinary Oncologist at Moffitt Cancer Center. In this video, he speaks about ASCO 2022 abstract CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG). Origins: CG0070 is an oncolytic vaccine based on Ad5 that has been modified to express GM-CSF and replicate selectively in tumor cells with mutant or defective RB. The mechanism of action of CG0070 comprises cell lysis and immunogenic cell death, which is accelerated in the presence of GM-CSF. In an open label phase 2 research, individuals with high risk NMIBC…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Doris Hansen, MD, Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. In this video, she speaks about the ASCO 2022 Abstract – Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Real-world experience. Origins: Ide-cel, a BCMA-directed CAR T-cell therapy, was approved by the FDA on March 26, 2021, for the treatment of RRMM after four prior lines of therapy. We looked at the real-world outcomes of patients who received standard-of-care ide-cel under a commercial FDA label. Methodology: Independent of the company, ten…

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale University. In this video, he speaks about the ASCO 2022 Abstract – Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about the ASCO 2022 Late-Breaking Abstract – Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.  Origins: Most…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Sumanta (Monty) Pal, MD, FASCO, Professor, Department of Medical Oncology & Therapeutics Research and Co-director, Kidney Cancer Program at City of Hope. In this video, he speaks about ASCO 2022 Abstract – Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study. Origins: C, a multitargeted receptor tyrosine kinase inhibitor (TKI), provides an immunological-permissive milieu that may boost immune checkpoint inhibitor responsiveness (ICIs). COSMIC-021, a multicenter phase 1b trial, is looking into C + A (anti-PD-L1 treatment) in a variety of solid tumors (NCT03170960). C + A indicated promising…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Karim Chamie, MD, Associate Professor of Urology and Society of Urologic Oncology Fellowship Director at UCLA Health. In this video, he speaks about the ASCO 2022 Abstract – Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC). Origins: Patients with NMIBC CIS who are not responding to BCG have few therapeutic choices. N-803 (Anktiva) is a mutant IL-15-based immunostimulatory fusion protein complex (IL15RaFc) that increases natural killer (NK) cell proliferation and activation but not regulatory T cell activation. In BCG-naive patients with NMIBC, phase 1b findings show that…

Clinical Data Management Tools Enables Flexibility and ScalabilitySupporting Evolving Oncology Clinical Study Designs   OncologyTube was privileged to feature Mike Keens, Executive Vice President, Anju Software (https://www.anjusoftware.com), and Stefan Michiels, Head of Department of Biostatistics and Epidemiology, Gustave Roussy (https://www.gustaveroussy.fr/en).  These gentlemen discussed key aspects of oncology clinical trial enrollment challenges and solutions, especially during and post COVID-19 pandemic.   At the outset of COVID-19 during the first quarter of 2020, enrollment within most clinical trials stopped – apart from COVID-19 vaccine trials.  Between March 2020 and May 2020, all ongoing trials scrambled to continue visits at home or attempted…

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL. A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Aaron Logan, MD, Ph.D., Hematologist, Associate Professor of Clinical Medicine at UC San Francisco. In this video, he speaks about The Treatment Landscape Of ALL.   A form of blood and bone marrow malignancy that affects white blood cells. The most frequent type of juvenile cancer is acute lymphoblastic leukemia. It happens when a bone marrow cell’s DNA becomes faulty. Enlarged lymph nodes, bruising, fever, bone discomfort, gum bleeding, and repeated infections are all possible symptoms. Chemotherapy or targeted medications that precisely kill cancer cells may be used as treatments.

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of Urology Weill Cornell Medicine Assistant Professor Casewestern and Yaw Nyame, MD, MS, MBA, Assistant Professor, Surgeon, Researcher at the University of Washington. In this video, they discuss the AUA 2022 abstract – LBA01-01: Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black Men.   Details   Spyridon Basourakos, Roman Gulati, Randy Vince, Daniel Spratt, Patrick Lewicki, Alexander Hill, Yaw Nyame, Jennifer Cullen, Sarah Markt, Christopher Barbieri, Jim Hu, and Jonathan Shoag are among the authors.   Intro:   Prostate-specific…

Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. In this video, he speaks about Prostate Cancer OS Is Up Significantly.   Observation –   Intention:   Orteronel (TAK-700) is a nonsteroidal androgen-suppressing 17,20-lyase inhibitor. We looked at how orteronel performed when combined with androgen deprivation therapy (ADT) in individuals with newly diagnosed metastatic hormone-sensitive prostate cancer.   Methodology:   Patients with metastatic hormone-sensitive prostate cancer were randomly…